Browse our comprehensive archive of press releases by date.
Select a specific day to access all press releases published on Middle East News Digest.
Press releases published on May 15, 2025
Lipella Pharmaceuticals to Present Phase 2a Data for LP-310 in Oral Lichen Planus at 2025 AAOM/EAOM International Meeting
GlobeNewswire
·
May 15, 2025
Statistically significant safety and efficacy data from 0.25 mg and 0.50 mg cohorts to be presented Presentation scheduled for Thursday, May 15, 2025, at 11:36 a.m. PT PITTSBURGH, May 15, 2025 (GLOBE NEWSWIRE) -- Lipella Pharmaceuticals Inc. (Nasdaq: LIPO) …
Micropolis to Present at the Aegis Capital Corp. 2025 Virtual Conference on May 20th
GlobeNewswire
·
May 15, 2025
DUBAI, United Arab Emirates, May 15, 2025 (GLOBE NEWSWIRE) -- Micropolis Holding Co. (“Micropolis” or the “Company”) (NYSE: MCRP), a pioneer in unmanned ground vehicles and AI-driven security solutions, today announced that its management team is scheduled …
Medicines for Poland: Europe Faces a Critical Choice on Medicines and Market Reform
GlobeNewswire
·
May 15, 2025
WARSAW, Poland, May 15, 2025 (GLOBE NEWSWIRE) -- Member States are nearing the end of discussions on EU pharmaceutical reform to ensure affordable medicines and support EU manufacturing in Europe. This will enhance the Union’s strategic resilience and …
SELLAS Life Sciences Announces First Pediatric AML Patient Dosed in the Ongoing Phase 2 Trial of SLS009 r/r AML
GlobeNewswire
·
May 15, 2025
NEW YORK, May 15, 2025 (GLOBE NEWSWIRE) -- SELLAS Life Sciences Group, Inc. (NASDAQ: SLS) (“SELLAS’’ or the “Company”), a late-stage clinical biopharmaceutical company focused on the development of novel therapies for a broad range of cancer indications, …
GRI Bio Reports First Quarter 2025 Financial Results and Confirms GRI-0621 Phase 2a IPF Trial on Track for 6-Week Interim Data in Q2 2025 and Topline Data in Q3 2025
GlobeNewswire
·
May 15, 2025
Positive interim 2-week safety and biomarker results from its ongoing Phase 2a study evaluating GRI-0621 for the treatment of Idiopathic Pulmonary Fibrosis (“IPF”) Continued momentum with completed patient enrollment for the 6-week interim analysis (n=24) …
ParaZero to Present Next-Generation Drone Safety Innovations & New CUAS Net Launcher at XPONENTIAL 2025
GlobeNewswire
·
May 15, 2025
Kfar Saba, Israel, May 15, 2025 (GLOBE NEWSWIRE) -- ParaZero Technologies Ltd. (Nasdaq: PRZO) (the "company” or “ParaZero”), an aerospace company focused on safety systems for commercial unmanned aircrafts and defense Counter UAS systems, is set to …
CorMedix Inc. to Participate in the RBC Global Healthcare Conference
GlobeNewswire
·
May 15, 2025
BERKELEY HEIGHTS, N.J., May 15, 2025 (GLOBE NEWSWIRE) -- CorMedix Inc. (Nasdaq: CRMD), a biopharmaceutical company focused on developing and commercializing therapeutic products for life-threatening diseases and conditions, will be participating in the RBC …
Odysight.ai Reports Financial Results for The First Quarter of 2025 and Provides Business Update
GlobeNewswire
·
May 15, 2025
OMER, Israel, May 15, 2025 (GLOBE NEWSWIRE) -- Odysight.ai Inc. (NASDAQ: ODYS), a leading provider of visual based predictive maintenance (PdM) and condition-based monitoring (CBM) solutions, announces its financial results for the three months ended March …
Reflect Scientific Advances Market Presence by Transitioning from OTCQB to OTCIQ
GlobeNewswire
·
May 15, 2025
OREM, Utah, May 15, 2025 (GLOBE NEWSWIRE) -- Reflect Scientific, Inc. (Symbol: RSCF), a provider of innovative cryogenic technologies for the life sciences and biotech industries, today announced that it is actively transitioning from the OTCQB Venture …
Cocrystal Pharma Reports First Quarter 2025 Financial Results and Provides Updates on its Antiviral Drug-Development Programs
GlobeNewswire
·
May 15, 2025
In vitro testing with CDI-988 demonstrated superior broad-spectrum antiviral activity against major norovirus variants BOTHELL, Wash., May 15, 2025 (GLOBE NEWSWIRE) -- Cocrystal Pharma, Inc. (Nasdaq: COCP) (“Cocrystal” or the “Company”) reports financial …
Vaxart Receives BARDA Approval to Initiate Dosing in 10,000-Participant Portion of Phase 2b COVID-19 Trial
GlobeNewswire
·
May 15, 2025
SOUTH SAN FRANCISCO, Calif., May 15, 2025 (GLOBE NEWSWIRE) -- Vaxart, Inc. (Nasdaq: VXRT) today announced that it has received approval from the Biomedical Advanced Research and Development Authority (BARDA), part of the Administration for Strategic …
Amneal Receives U.S. FDA Approval for Brekiya® (dihydroergotamine mesylate) injection for the Acute Treatment of Migraine and Cluster Headaches in Adults
GlobeNewswire
·
May 15, 2025
Brekiya® becomes the first and only DHE autoinjector that allows patients to self-administer the same medication used in hospitals in a ready-to-use form Product will be available for appropriate patients in the second half of 2025 BRIDGEWATER, N.J., May …
Bitcoin Solaris Launches Enterprise-Grade Security Framework Ahead of Nova App Release
GlobeNewswire
·
May 15, 2025
TALLINN, Estonia, May 15, 2025 (GLOBE NEWSWIRE) -- Bitcoin Solaris has officially rolled out its enterprise-grade security framework, establishing the technical foundation for the upcoming Nova App launch and broader public participation in its blockchain …
Polpharma Group fordert dringende Maßnahmen zum Schutz eines frühzeitigen und gerechten Zugangs zu Medikamenten für europäische Patienten
GlobeNewswire
·
May 15, 2025
WARSCHAU, Polen, May 15, 2025 (GLOBE NEWSWIRE) -- Die Polpharma Group, ein führendes Pharmaunternehmen, fordert die Europäische Union nachdrücklich auf, entschlossene Maßnahmen zu ergreifen, um die Arzneimittelreform abzuschließen und die Kapazitäten …
Polpharma Group plaide en faveur d’une action urgente en vue de garantir aux patients européens un accès équitable et précoce aux médicaments
GlobeNewswire
·
May 15, 2025
VARSOVIE, Pologne, 15 mai 2025 (GLOBE NEWSWIRE) -- Polpharma Group, acteur pharmaceutique de première importance, enjoint l’Union européenne à arrêter des mesures décisives pour finaliser la réforme du secteur pharmaceutique et renforcer la capacité du …
N2OFF Energy Targets European’s Energy Crises with Fourth Regional Battery Project
GlobeNewswire
·
May 15, 2025
N2OFF to take part in financing a 35MW/140MWh planned Battery Energy Storage System project in Poland Neve Yarak, Israel, May 15, 2025 (GLOBE NEWSWIRE) -- N2OFF, Inc.(NASDAQ: NITO) (FSE:80W) (“N2OFF” and the “Company”), a clean tech company engaged in …
Skyharbour and JV Partner Orano to Commence Extensive Summer 2025 Drilling Program at Preston Uranium Project
GlobeNewswire
·
May 15, 2025
Vancouver, BC, May 15, 2025 (GLOBE NEWSWIRE) -- Skyharbour Resources Ltd. (TSX-V: SYH) (OTCQX: SYHBF) (Frankfurt: SC1P) (“Skyharbour” or the “Company”), is pleased to announce that its joint-venture partner, Orano Canada Inc. (“Orano”), will commence a …
Avicanna Reports Q1 2025 Results and First Profitable Quarter
GlobeNewswire
·
May 15, 2025
TORONTO, May 15, 2025 (GLOBE NEWSWIRE) -- Avicanna Inc. (“Avicanna” or the “Company) (TSX: AVCN) (OTCQX: AVCNF) (FSE: 0NN) a biopharmaceutical company focused on the development, manufacturing, and commercialization of plant-derived cannabinoid-based …
Zenas BioPharma Reports First Quarter 2025 Financial Results and Provides Corporate Updates
GlobeNewswire
·
May 15, 2025
- Topline results from pivotal Phase 3 INDIGO trial in Immunoglobulin G4-Related Disease expected around year-end 2025 - - Phase 2 MoonStone trial in Relapsing Multiple Sclerosis enrollment concluding; topline results expected early in the fourth quarter …
Invivyd Reports First Quarter 2025 Financial Results and Recent Business Highlights
GlobeNewswire
·
May 15, 2025
PEMGARDA™ (pemivibart) net product revenue of $11.3 million reported for Q1 2025, influenced by planned transition (Jan/Feb) from a contracted to an internalized sales force PEMGARDA revenue re-acceleration observed in Q2 2025 to date Invivyd continues to …